Rapport Therapeutics, Inc. Common Stock logo

Rapport Therapeutics, Inc. Common Stock(RAPP)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$26.15
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RAPP

11/13/2026: RAPP (2-star) is currently NOT-A-BUY. Pass it for now.

Rapport Therapeutics is a clinical-stage biotechnology company developing precision medicines for neurological disorders through its proprietary RECEP platform. The company's main strength lies in its specialized technology, which aims to improve drug efficacy and safety in complex conditions like epilepsy. Its investment story centers on the success of its lead candidate, RAP-140, as it progresses through clinical trials. However, as an early-stage firm, it faces high execution, clinical, and competitive risks, and currently generates no revenue. This stock is best suited for growth-oriented investors with high risk tolerance, and observers should closely monitor clinical trial readouts and capital efficiency over the coming quarters.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high-risk, high-reward exposure to a cutting-edge clinical-stage biotechnology pipeline.
Momentum investorMixed fitMomentum status is conditional on positive clinical data readouts or specific news-driven catalysts in the biotech sector.
Value investorWeak fitThe company currently lacks revenue and earnings, making traditional valuation metrics inapplicable.
Dividend investorWeak fitThe firm is in a cash-burning growth phase and does not pay dividends.
Low-risk investorWeak fitClinical-stage biotech stocks are inherently highly volatile and carry significant binary trial risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks often experience extreme price swings based on clinical trial results and regulatory news.
Valuation riskMedium / highValuations are speculative and depend heavily on future success probabilities rather than current cash flows.
Competition risk (Neurology drug market)HighThe company competes against large, well-funded pharmaceutical firms with established market presence.
Business qualityMediumThe business relies on a proprietary platform that has yet to be fully validated by commercialized products.
Dividend incomeLow / noneThe company does not generate the earnings necessary to support dividend payments.
Execution riskHighSuccess depends on the complex, uncertain process of clinical trial design, patient enrollment, and regulatory approval.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.55B USD
Price to earnings Ratio -
1Y Target Price 64.21
Price to earnings Ratio -
1Y Target Price 64.21
Volume (30-day avg) 1.2M shares
Beta 1.4
52 Weeks Range 22.06 - 52.93
Updated Date 11/14/2026
52 Weeks Range 22.06 - 52.93
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -23.32%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RAPP receives a 3-star rating, supported by strong analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
RAPP has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-42.4%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
RAPP's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
RAPP's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-42.4%, negative) and free-cash-flow growth (-31.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 89.1% and approximately 75.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.16% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 12.40%
TRV GP V, LLC 10.86%
ARCH VENTURE CORP 6.45%
Capital Research & Mgmt Co - Division 3 5.05%
The Goldman Sachs Group Inc 5.03%

Unit Economics (Per $1K Revenue)

★★★★★
RAPP generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
RAPP has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Research and DevelopmentAdvancing drug candidates like RAP-140 and RAP-219 through clinical trials.The company currently does not sell products and is entirely focused on creating value by proving its drugs work.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.15B
Price to Sales(TTM) 77.51
Enterprise Value 1.15B
Price to Sales(TTM) 77.51
Enterprise Value to Revenue 57.34
Enterprise Value to EBITDA -
Shares Outstanding 59.28M
Shares Floating 44.87M
Shares Outstanding 59.28M
Shares Floating 44.87M
Percent Insiders 3.16
Percent Institutions 89.14

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.